REG - Futura Medical PLC - Total Voting Rights

Futura MedicalAnnouncement

31/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251231:nRSe1475Na&default-theme=true

RNS Number : 1475N  Futura Medical PLC  31 December 2025

31 December 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

Total Voting Rights

 

Futura Medical plc (AIM: FUM), the pharmaceutical company developing
innovative sexual health products, announces that for the purposes of the
FCA's Disclosure and Transparency Rules, the Company's total issued share
capital at the date of this announcement is 581,327,755 Ordinary Shares.

 

Since the Company currently holds no shares in treasury, the total number of
voting rights in the Company is 581,327,755 and this figure may therefore be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
in their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Emma Thompson       +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFZMFZGGLGKZM



            Copyright 2019 Regulatory News Service, all rights reserved